[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350564-105":59,"doc-detail-350564-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","nrf1-predominantly-causes-ezh2-overexpression-in-cancer-cells","NRF1 predominantly causes EZH2 overexpression in cancer cells","","NRF1 predominantly drives EZH2 overexpression across cancer cell lines, and changes in NRF1 expression reliably alter EZH2 expression. As a transcription factor, NRF1 directly binds the NRF1-binding sequence within the EZH2 promoter, increasing promoter activity; disrupting this DNA-binding motif abolishes the effect. NRF1 expression status also modulates sensitivity to EZH2 inhibitors such as GSK343 and tazemetostat, with strongest sensitivity when NRF1 and EZH2 are coexpressed.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/nrf1-predominantly-causes-ezh2-overexpression-in-cancer-cells/350564/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/nrf1-predominantly-causes-ezh2-overexpression-in-cancer-cells/350564.png","ImageObject",300,407,{"name":92,"@type":93},"Bulrr","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What role does NRF1 play in EZH2 overexpression in cancer cells?","Question",{"text":113,"@type":114},"NRF1 predominantly drives EZH2 overexpression. Altering NRF1 expression changes EZH2 expression across cancer cell lines in a consistent manner.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does NRF1 regulate EZH2 at the molecular level?",{"text":118,"@type":114},"NRF1 acts as a transcription factor that directly binds the NRF1-binding sequence in the EZH2 promoter and increases EZH2 promoter activity.",{"name":120,"@type":111,"acceptedAnswer":121},"How does NRF1 expression affect response to EZH2 inhibitors?",{"text":122,"@type":114},"Cancer cells coexpressing NRF1 and EZH2 show significantly higher sensitivity to EZH2 inhibitors like GSK343 and tazemetostat, compared with cells expressing either factor alone or low levels of both.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},350564,1790177641,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":41,"preview_page_count":19,"preview_urls":146},5909892115043,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nNRF1 predominantly causes EZH2 overexpression in cancer cells  \nJuanli Qiao1,2, Zhaojun Liu1,2, Liankun Gu1 and Dajun Deng 1 ✉  \n© The Author(s) 2026  \n|  |  |  |\n| --- | --- | --- |\n|  | EZH2 is an oncogene and therapeutic target. Only a small proportion of cancer patients beneﬁt from treatment with EZH2 inhibitors (EZH2is) . The mechanisms underlying EZH2 overexpression and EZH2i resistance are not clear. Here, we report that the nuclear respiratory factor 1 gene (NRF1) is the gene whose expression is most strongly correlated with that of the EZH2 gene in various cancer cell lines and that changes in NRF1 expression consistently cause changes in EZH2 expression in cancer cells. Mechanistically, as a transcription factor, NRF1 directly binds to the NRF1-binding sequence within the EZH2 promoter and increases EZH2 promoter activity. Deletion of the DNA-binding motif within the NRF1 or NRF1-binding sequence within the EZH2 promoter abolishes the effects of NRF1 on EZH2 expression. Notably, we further found that the status of NRF1 expression affected the sensitivity of human cancer cells to EZH2is, including GSK343 and tazemetostat. The sensitivity of cancer cells actively expressing both NRF1 and EZH2 to EZH2i is signiﬁcantly greater than that of cancer cells actively expressing individual EZH2 or NRF1 alone and much greater than that of cancer cells expressing low levels of EZH2 and NRF1 . The effect of NRF1 on the sensitivity of cancer cells to EZH2is is EZH2 dependent. In conclusion, our ﬁndings reveal that NRF1 is a dominant cause of EZH2 overexpression in human cancers and that NRF1 overexpression increases the sensitivity of cancer cells to EZH2is. Active NRF1 and EZH2 expression may be a useful combined |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| predictor for the treatment of cancers with EZH2is. |  |  |\n|  | Cell Death and Disease (2026)17:625; [https://doi.org/10.1038/s41419-026-08861-4](https://doi.org/10.1038/s41419-026-08861-4) |  |\n|  |  |  |\n\nSIGNIFICANCE  \nWe found that NRF1, as a transcription factor, predominantly drives EZH2 overexpression in cancers, and high NRF1 and EZH2 coexpression is a predictor of the sensitivity of cancer cells to EZH2 inhibitors.  \nINTRODUCTION  \nThe epigenetic modulator Enhancer of Zeste Homolog 2 (EZH2) is the core catalytic subunit of Polycomb Repressive Complex 2 (PRC2), which typically represses the transcription of target genes by catalyzing the trimethylation of lysine 27 of histone H3 (H3K27me3) in chromatin and activating target gene transcription via a noncanonical pathway [1] . Whereas EZH2 physiologically regulates a wide range of biological processes, including cell cycle progression, autophagy, apoptosis, DNA damage responses, cellular senescence, and cell fate decisions [2–5], it is also universally overexpressed in human cancers across many organs as a master determinant of cancer phenotypes [6–12] . EZH2 overexpression not only enhances cancer cell proliferation, migration, and invasion but also leads to poor prognosis in cancers [11, 12] . However, the mechanisms underlying EZH2 overexpression in cancer cells remain unclear.  \nAs a cancer driver, EZH2 overexpression is a therapeutic target in the treatment of cancers. For example, the EZH2 inhibitors  \n(EZH2is) tazemetostat and valemetostat have been approved for the treatment of non-Hodgkin’s lymphoma, rare adult sarcoma, and T-cell leukemia/lymphoma [13–16]. A number of other EZH2is, such as GSK343 [17] and GSK126 [18], are under development. EZH2is may inhibit the growth of cancer cells not only by blocking H3K27me3 modiﬁcation but also by improving immunotherapy responses through reactivating antigenic retrovirus elements in the genome [17, 19, 20] . Unfortunately, EZH2i resistance is unavoidable [21, 22], and clinical biomarkers to predict the efﬁciency of EZH2is are","cbCaitxH03cLxFzX","https://ap.wps.com/l/cbCaitxH03cLxFzX","pdf",6313527,12,"English","# Significance\n# Introduction\n## EZH2 biology and therapeutic relevance\n## NRF1 functions in mitochondria and cancer\n## Study rationale and objectives\n# Materials and Methods","[{\"question\":\"What role does NRF1 play in EZH2 overexpression in cancer cells?\",\"answer\":\"NRF1 predominantly drives EZH2 overexpression. Altering NRF1 expression changes EZH2 expression across cancer cell lines in a consistent manner.\"},{\"question\":\"How does NRF1 regulate EZH2 at the molecular level?\",\"answer\":\"NRF1 acts as a transcription factor that directly binds the NRF1-binding sequence in the EZH2 promoter and increases EZH2 promoter activity.\"},{\"question\":\"How does NRF1 expression affect response to EZH2 inhibitors?\",\"answer\":\"Cancer cells coexpressing NRF1 and EZH2 show significantly higher sensitivity to EZH2 inhibitors like GSK343 and tazemetostat, compared with cells expressing either factor alone or low levels of both.\"}]","NRF1 predominantly causes EZH2 overexpression in cancer cells | PDF",1790089641,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cd20157827b153099be765bf5efe695f.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d85beca95562d8df8c37d077dce27dfa.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd5aa2fe89dc9ca87b78086c00e71f81.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fd9dedaee73b68291f02337c8a74acfd.webp",980,1301]